ENTITY
Akeso Biopharma Inc

Akeso Biopharma Inc (9926 HK)

211
Analysis
Health CareChina
Akeso Inc. operates operatesa s a biotech company. The compnay develops treatments and therapies for various types of diseases. Akeso serves cutomers worldwide
more
02 Dec 2024 08:55

2025 High Conviction – China Healthcare: Chinese Biotech to Compete on the International Stage

​Akeso's investment certainty increases based on promising HARMONi-2 data, leading to potential market value surpassing Innovent and reaching above...

Logo
369 Views
Share
14 Oct 2024 08:55

Akeso Biopharma Placement - The Placing Price Is Not Cheap Despite Positive Business Progress

​Akeso delivers impressive HARMONi-2 data, which greatly increases the possibility of positive OS. But the market cap already partially reflects...

Logo
467 Views
Share
10 Oct 2024 19:38

Akeso Placement - Opportunistic Raise, past Deal Record Has Been Mixed but Relative Size Is Small

Akeso Biopharma Inc (9926 HK) is looking to raise around US$200m from its primary placement. Proceeds from the placement will be used for R&D.

Logo
454 Views
Share
11 Sep 2024 08:55

Akeso Biopharma Inc (9926 HK) - Something Beautiful Is Happening

​AK112's HARMONi-2 results show promise, but FDA approval depends on OS. Summit is actually a better investment than Akeso. Investors bet Summit to...

Logo
345 Views
Share
03 Sep 2024 18:46

[Akeso Inc. (9926 HK, BUY, TP HK$63) TP Change]: Too Many Positives to Count…Reiterate TOP BUY

​Akeso reports better-than-expected financial results, with positive Phase III start for CD-47 mAb (AK117) leading to a raised price target and top...

Share
x